Rate My Professor Jean Giacomotto

Giacomotto's research integrates phenotypic screening, chemical genetics, CRISPR/Cas9 genome editing, and transgenic technologies to model disease phenotypes and identify therapeutic compounds. Key impacts include zebrafish-based functional assays that have guided clinical decisions, such as avoiding multi-million-dollar SMA treatments for infants with benign gene variants, as demonstrated in world-first studies published in 2026. His investigations have contributed to bioactive molecules reaching the market, improving patient outcomes. Prominent publications include 'High-throughput screening and small animal models, where are we?' (2010), 'Neurexins in autism and schizophrenia—a review of patient mutations, mouse models and potential future directions' (2021), and 'Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish' (2021). He has received funding from the NHMRC Emerging Leader Fellowship, Metro South Health Research Grants, and the Australian Functional Genomics Network. Giacomotto also teaches courses like Science Capstone (3992NSC) and Advanced Studies Tasks (2601SCG, 2602SCG), supervises higher-degree research students, and advances translational biomedicine through innovative screening platforms.